York Zhu, Ph.D.

Chairman, Chief Executive Officer

York Zhu, Chairman, CEO and Founder of Biomics Biotechnologies co. Ltd. (Nantong, China). He has dedicated in the development of nucleotide technologies and industrialization for over 20 years.

In 1993, Dr. Zhu received his PhD in Medical School of Nagoya University (Nagoya, Japan). From 1993 to 1999, he started his industrial R&D career at Clontech Lab (California, USA) as a researcher followed by R&D manager and biological technical consultant in University of Georgia (Georgia, USA). At Clontech, he led a team and contributed cDNA and cloning product line which had a great of significance when company merged with BD.

From 1999 to 2003, Dr. Zhu worked as Chief Technology Officer and also technical share holder in Genemed R&D headquarter. During the four years, his main focus was on research and developing new nucleotide drugs and invented GET/FLAGS technology. In the next two years, he worked as Vice President and Chief Technology Officer in Zytogene (California, USA), a subsidiary of Genemed. At Zytogene, he led a R&D team and managed to develop over 200 new products which contributed a great deal in acquisition by Invitrogen.

In 2005, he founded NT Omics (California, USA) where he invented Entire siRNA Targets (EsT) library which opens a field in RNAi technology. In 2006, he founded Biomics Biotechnologies co. Ltd. specializing in researching and industrializing of RNAi technology.

Dr. Zhu has authored in over 40 scientific papers and have interventorship of more than 30 patents.

　Jinkang Wang, Ph.D. 　

Vice President, Chief Science Officer
(In charge of Chemical synthesis and Drug Safety Evaluation)

Dr. Jinkang Wang joined Biomics in 2008 bring 18 years experience in the creation and development of various nanoparticle drug delivery systems for anti-cancer drugs and biologics (antisense oligonucleotides, DNA, and siRNA). He was the inventor/co-inventor of 15 US patents. Prior to joining Biomics, Dr. Wang served as a senior scientist for several biopharmaceutical companies including Alza Corp. (Johnson & Johnson), NeoPharm, Inc., Genteric, Inc., and Valentis, Inc.. He possesses broad expertise that spans several areas including chemical structure design and synthesis, early formulation research, process development, and manufacturing under cGMP guidance. He participated in the development of one product to market, and three products in clinical trails. Most recently, his research has been involved in the drug delivery systems including targeted second generation stealth-liposome and self-assembling co-polymers. Currently, his reaserch is more focused on the chemical modified siRNA.

Dr. Wang obtained his undergraduate education from Beijing Normal University, and then he served as a faculty member in teaching and research of organic chemistry at same University for nine years. He received his Ph.D. degree in Organic Chemistry from Marquette University in Wisconsin, US, and postdoctoral training in Biopharmaceutical Science at the University of California, San Francisco (UCSF).

　 Jay Chen, Ph.D. 　

Vice President, Chief Technology Officer
(In charge of Life science and Drug delivery)

Dr. Jay Chen joined Biomics in 2011. He has broad and profound chemical knowledge and 25 years' R&D experience in medicinal chemistry, process chemistry, product development and commercialization.

Before joining Biomics, Dr. Chen worked in several biopharmaceutical companies including AlCana Technologies Inc. (Director of medicinal chemistry R&D, Vancouver), Neuftech Chemicals Ltd. (Technology VP, Richmond), Kinetek Pharmaceuticals Inc. (Senior scientist, Vancouver). He also served as a key consultant at Alnylam Pharmaceuticals Inc. and at Tekmira Pharmaceuticals Inc., respectively based on his innovation in developing siRNA delivery system. He also has about 10 years experience in business development.

Dr. Chen obtained his Ph.D. in organic chemistry from University of British Columbia (Canada) in 1991, M.Sc in organic chemistry from Institute of Photographic Chem., Chinese Academy of Sciences in 1984. He has 28 papers published in leading journals, 4 granted and 3 filed patents, as well as numerous company confidential technical reports.

　 Kate Zhu, MBA

Vice President / Operation

Ms. Kate Zhu joined Biomics since it's' foundation as the Director of Operation. She contributed greatly on fund raising, planning construction of the Biomics' corporate center and development of Biomics' administrative systems.

In early 90s, Ms. Zhu served as the import-export manager in Jiangsu Technology Import and Export Corporation. She was responsible for contract negotiation、quality assurance and cost control. In middle 90s, Ms. Zhu went to the United States and in charge of company's business development in United States. Upon returning to China, she became the director of Jiangsu Technology Import and Export Corporation because of her achievement in USA and was responsible of company's marketing and sales department, developing market strategies and implemented sales expansion.

Prier joining Biomics, Kate Zhu was the founder and president of Linkone Inc., the earliest human resources consulting and recruitment firm in Nantong, where she got the experience on assessing、recruiting and retaining highly valuable employees for companies. She also owned a MBA Degree from the University of Northern Virginia.

　 Lee Shan, MBA

Vice President / Business and Market Development

Mr. Lee Shan has more than 15 years experience in Pharmaceutical Industry both in China and USA. Prior joining Biomics, Mr. Li Shan worked in AustarPharma Inc. in New Jersey as Business Development Director, where he helped company to start the partnership with Amerisourcebergen and Cardinal Health Group-2 giant whole sale companies in generic drug market. His experience in pharmaceutical industry also including the following aspects: research, assistant researcher in School of Medicine, the University of South Dakota (USA); marketing and sales, Sales Manager in Jintai Biotech Pharmaceutical Company; production, fermentation engineer in Qilu Pharmaceutical Company.

Mr. Lee Shan received his MBA degree in John Molson Business School, Concordia University, Canada in 2003. He also owned a master degree on Bio-medical in School of Medicine, University of South Dakota, USA (1999) and a bachelor degree of Microbiology from Shandong University (1988).